Mecobalamin and early functional outcomes of ischemic stroke patients with H-type hypertension

摘要

OBJECTIVE: To analyze the effect of mecobalamin on the early-functional outcomes of patients with ischemic stroke and H-type hypertension.METHODS: From October of 2014 to October of 2016, 224 cases of ischemic stroke and H-type hypertension were selected. The patientswere randomly divided into treatment control groups, with 112 patients in each group. The control group was treated with the conventionaltherapy. The observation group was treated with 500 μg of mecobalamin three times a day in addition to the conventionaltherapy. We compared serum homocysteine (Hcy), hs-CRP levels, carotid plaques, and NIHSS scores between the two groups on the2nd day and at 4 weeks, 8 weeks, 3 months, and 6 months.RESULTS: After 4 weeks, 8 weeks, 3 months and 6 months, the difference of serum Hcy level between the two groups was statisticallysignificant (t = 4.049, 3.896, 6.052, 6.159, respectively. All P <0.05). After the treatment, at 4 weeks, 8 weeks, 3 months and 6 months,the levels of hs-CRP in the treatment group were significantly lower than those in the control group (t = 37.249, 28.376, 26.454, 20.522,respectively. All P <0.01). After 3 months and 6 months, the carotid artery plaques were significantly reduced in the treatment groupcompared to those in the control group (t = 2.309 and 2.434. All P <0.05). After 3 months and 6 months, the NIHSS score was significantlyhigher in the treatment group compared to those in the control group (t = 2.455 and 2.193. All P <0.05).CONCLUSION: Mecobalamin can reduce the level of plasma homocysteine, then lead to reductions of levels of plasma inflammatoryfactors and volume of carotid artery plaques, resulting in more significant functional recovery.